|Articles|January 29, 2014

GEA Process Engineering A/S

Spray drying is an ultra-fast and gentle drying technology that offers unique possibilities of producing powders with advanced properties.

GEA Process Engineering A/S

Improve drug properties and production with spray drying
Spray drying is a technique preferred by a growing number of pharmaceutical companies to produce better drugs. This ultra-fast and gentle drying technology offers unique possibilities of producing powders with advanced properties - even under aseptic conditions.

Several companies are already benefitting from the technology as an ‘enabling technology’ - to improve the performance of poorly soluble APIs by producing an amorphous solid dispersion, to obtain controlled release or taste-masking, or to produce advanced powders with specific properties.

GEA Process Engineering - the company behind GEA Niro spray drying technology - is the leading provider of spray drying technology to the pharmaceutical industry, and is one of the few companies that offer a full range of spray drying units and services to companies working with the develop-ment of spray dried pharmaceuticals and pharmaceutical grade products. Our portfolio covers the complete development cycle - from the initial proof of concept tests where only a few milliliters of material are available to full-scale production of clinical trial materials and commercial products under cGMP conditions. For better results on any scale, look to GEA Process Engineering.

Website:www.niro.comE-mail:[email protected]

Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.